Medical Equipment & Devices

FNArena Windows (Sectors)

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories

Following FY22 results, brokers set higher price targets for ResMed on average and expect market share gains

Aug 15 2022

Dedicated lung imaging pioneer 4D medical sees itself as a software company, with lots of future potential, including from the US military

Aug 08 2022


ASX CODE COMPANY NAME LAST PRICE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET
CBL CONTROL BIONICS LIMITED $0.18 $0.66 $0.12

$0.85

COH COCHLEAR LIMITED $208.36 $236.43 $178.55 44.1

$217.783

EBR EBR SYSTEMS INC $0.52 $1.10 $0.33

$1.38

FPH FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED $16.83 $33.01 $16.18 51.9

$19.50

IDX INTEGRAL DIAGNOSTICS LIMITED $2.80 $5.13 $2.38 20.6

$3.086

IME IMEXHS LIMITED $0.47 $xx.xx $xx.xx xx.x xx.xx
IPD IMPEDIMED LIMITED $0.06 $xx.xx $xx.xx xx.x xx.xx
MX1 MICRO-X LIMITED $0.17 $xx.xx $xx.xx xx.x xx.xx
NAN NANOSONICS LIMITED $3.50 $xx.xx $xx.xx xx.x xx.xx
PME PRO MEDICUS LIMITED $53.16 $xx.xx $xx.xx xx.x xx.xx
RMD RESMED INC $33.81 $xx.xx $xx.xx xx.x xx.xx
SOM SOMNOMED LIMITED $1.40 $xx.xx $xx.xx xx.x xx.xx
TRJ SOMNOMED LIMITED $2.04 $xx.xx $xx.xx xx.x xx.xx
VHT VOLPARA HEALTH TECHNOLOGIES LIMITED $0.55 $xx.xx $xx.xx xx.x xx.xx
Previous Stories
Treasure Chest: The Outlook For Cochlear

Jul 27 2022

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Today’s idea regards Cochlear


Nanosonics’ Q4 Surprises, But Brokers See Risk

Jul 27 2022

Nanosonics’ June quarter update proved a positive surprise but most brokers cannot get past the many risks, also finding the shares look expensive


Benefits In View For Radiology AI Adopters

Jul 11 2022

After a huge step up in funding over the last three years, artificial intelligence in radiology may be approaching wider adoption across the sector


Brokers Divided Over ResMed’s SaaS Acquisition

Jun 16 2022

Following ResMed’s purchase of Medifox Dan, brokers remain upbeat though some question the benefits of SaaS acquisitions to date


Shortages Chip Away At ResMed’s Big Break

Mar 30 2022

ResMed has struggled to realise the benefit promised by a major competitor recall and heightened demand amid a global shortage of semiconductor chips necessary for device production


Opportunity for Fisher & Paykel Healthcare

Mar 25 2022

With a potential end in sight for Fisher & Paykel Healthcare’s covid benefits the company looks to prove its ventilation devices have a place outside of intensive care units and rebuild utilisation rates for a sustainable outlook


Distribution Anxiety For Nanosonics

Feb 10 2022

Disappointment over first half sales and an abrupt change to a US distribution agreement sent shares of Nanosonics lower, though some brokers see value emerging


Brokers Awake To ResMed’s Potential

Jan 31 2022

Brokers remain positive on the outlook for ResMed due to a new product launch and the potential for both increased market share and the easing of supply chain pressures


Covid Benefits F&P Healthcare, For Now

Dec 06 2021

Normalisation appears to be on the horizon for Fisher & Paykel Healthcare, after hardware sales have continued to benefit from covid hospitalisations longer than anticipated


Will Shortages Limit Upside For ResMed?

Nov 01 2021

Some market share is likely to stick with ResMed as Philips struggles to replace its recalled device. Yet will supply chain constraints limit the benefit?